(PRME) Prime Medicine, Common Stock - Overview
Stock: Gene Editing, Prime Editor, PegRNA, Cell Shielding, Immunotherapy
| Risk 5d forecast | |
|---|---|
| Volatility | 96.3% |
| Relative Tail Risk | -6.77% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 0.82 |
| Alpha | 7.01 |
| Character TTM | |
|---|---|
| Beta | 1.914 |
| Beta Downside | 2.003 |
| Drawdowns 3y | |
|---|---|
| Max DD | 94.53% |
| CAGR/Max DD | -0.46 |
Description: PRME Prime Medicine, Common Stock December 30, 2025
Prime Medicine, Inc. (NASDAQ: PRME) is a Cambridge-based biotech that commercializes its proprietary “Prime Editing” platform-a CRISPR-derived, single-turnover gene-editing system that inserts precise DNA changes without inducing double-stranded breaks. The technology combines a catalytically-improved Cas9 nickase, a reverse-transcriptase (RT) domain, and a pegRNA that both locates the target site and encodes the desired edit. Prime Medicine’s current focus is on partnership-driven programs, most notably a research collaboration with Cimeio Therapeutics to create “Prime-Edited Shielded-Cell & Immunotherapy” pairs for genetic diseases, acute myeloid leukemia (AML), and myelodysplastic syndromes (MDS). The company was incorporated in 2019 and trades as a common stock in the U.S. biotechnology sub-industry.
As of the most recent 10-Q (Q3 2024), PRME reported cash and cash equivalents of roughly $150 million, a monthly cash burn of ≈ $12 million (≈ $144 million annualized), and R&D spending representing 68 % of total operating expenses-typical for early-stage gene-editing firms. The market capitalization hovered around $550 million, implying a price-to-sales multiple of ~ 30× based on projected 2025 revenue from anticipated licensing deals and early-stage therapeutic milestones. These metrics suggest the company is still runway-constrained and highly dependent on successful pre-clinical data to unlock partnership funding.
The broader gene-editing sector is being driven by three macro forces: (1) a projected CAGR of ~ 15 % through 2030 for the global gene-therapy market (≈ $15 billion by 2030), (2) increasing FDA comfort with non-viral, precise editing approaches after the approval of base-editing therapies, and (3) escalating venture and strategic capital inflows-U.S. biotech IPO proceeds reached a 5-year high of $12 billion in 2023, providing a favorable fundraising environment for companies like Prime Medicine.
For a deeper, data-rich view of PRME’s valuation dynamics, you may find ValueRay’s analyst toolkit useful.
Piotroski VR‑10 (Strict, 0-10) 0.0
| Net Income: -197.3m TTM > 0 and > 6% of Revenue |
| FCF/TA: -0.30 > 0.02 and ΔFCF/TA 27.30 > 1.0 |
| NWC/Revenue: 3286 % < 20% (prev 324.0%; Δ 2962 % < -1%) |
| CFO/TA -0.28 > 3% & CFO -109.1m > Net Income -197.3m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 6.61 > 1.5 & < 3 |
| Outstanding Shares: last quarter (160.5m) vs 12m ago 34.02% < -2% |
| Gross Margin: error (current vs previous; cannot be calculated due to missing/invalid data or negative margin) |
| Asset Turnover: 1.67% > 50% (prev 19.31%; Δ -17.65% > 0%) |
| Interest Coverage Ratio: -62.02 > 6 (EBITDA TTM -193.4m / Interest Expense TTM -3.23m) |
Altman Z'' -11.50
| A: 0.51 (Total Current Assets 231.4m - Total Current Liabilities 35.0m) / Total Assets 385.0m |
| B: -2.19 (Retained Earnings -842.3m / Total Assets 385.0m) |
| C: -0.56 (EBIT TTM -200.6m / Avg Total Assets 358.9m) |
| D: -3.77 (Book Value of Equity -842.2m / Total Liabilities 223.2m) |
| Altman-Z'' Score: -11.50 = D |
What is the price of PRME shares?
Over the past week, the price has changed by -6.30%, over one month by -3.51%, over three months by -14.59% and over the past year by +41.67%.
Is PRME a buy, sell or hold?
- StrongBuy: 6
- Buy: 2
- Hold: 4
- Sell: 0
- StrongSell: 0
What are the forecasts/targets for the PRME price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 6.5 | 81% |
| Analysts Target Price | 6.5 | 81% |
| ValueRay Target Price | 3.1 | -14.3% |
PRME Fundamental Data Overview February 03, 2026
P/B = 4.6293
Revenue TTM = 5.98m USD
EBIT TTM = -200.6m USD
EBITDA TTM = -193.4m USD
Long Term Debt = 118.1m USD (from capitalLeaseObligations, last quarter)
Short Term Debt = 7.71m USD (from shortTermDebt, last quarter)
Debt = 118.1m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 46.7m USD (from netDebt column, last quarter)
Enterprise Value = 597.5m USD (687.7m + Debt 118.1m - CCE 208.4m)
Interest Coverage Ratio = -62.02 (Ebit TTM -200.6m / Interest Expense TTM -3.23m)
EV/FCF = -5.19x (Enterprise Value 597.5m / FCF TTM -115.1m)
FCF Yield = -19.26% (FCF TTM -115.1m / Enterprise Value 597.5m)
FCF Margin = -1926 % (FCF TTM -115.1m / Revenue TTM 5.98m)
Net Margin = -3302 % (Net Income TTM -197.3m / Revenue TTM 5.98m)
Gross Margin = unknown ((Revenue TTM 5.98m - Cost of Revenue TTM 49.3m) / Revenue TTM)
Tobins Q-Ratio = 1.55 (Enterprise Value 597.5m / Total Assets 385.0m)
Interest Expense / Debt = 0.37% (Interest Expense 434.0k / Debt 118.1m)
Taxrate = 21.0% (US default 21%)
NOPAT = -158.5m (EBIT -200.6m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 6.61 (Total Current Assets 231.4m / Total Current Liabilities 35.0m)
Debt / Equity = 0.73 (Debt 118.1m / totalStockholderEquity, last quarter 161.8m)
Debt / EBITDA = -0.24 (negative EBITDA) (Net Debt 46.7m / EBITDA -193.4m)
Debt / FCF = -0.41 (negative FCF - burning cash) (Net Debt 46.7m / FCF TTM -115.1m)
Total Stockholder Equity = 120.7m (last 4 quarters mean from totalStockholderEquity)
RoA = -54.98% (Net Income -197.3m / Total Assets 385.0m)
RoE = -163.5% (Net Income TTM -197.3m / Total Stockholder Equity 120.7m)
RoCE = -83.98% (EBIT -200.6m / Capital Employed (Equity 120.7m + L.T.Debt 118.1m))
RoIC = -131.3% (out of range, set to none) (NOPAT -158.5m / Invested Capital 120.7m)
WACC = 11.11% (E(687.7m)/V(805.9m) * Re(12.97%) + D(118.1m)/V(805.9m) * Rd(0.37%) * (1-Tc(0.21)))
Discount Rate = 12.97% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 28.38%
Fair Price DCF = unknown (Cash Flow -115.1m)
EPS Correlation: 18.11 | EPS CAGR: -4.53% | SUE: 0.97 | # QB: 1
Revenue Correlation: 33.24 | Revenue CAGR: 151.2% | SUE: -0.11 | # QB: 0
EPS next Quarter (2026-03-31): EPS=-0.24 | Chg30d=-0.006 | Revisions Net=+0 | Analysts=5
EPS next Year (2026-12-31): EPS=-0.90 | Chg30d=+0.000 | Revisions Net=-2 | Growth EPS=+29.2% | Growth Revenue=+210.6%